What is Averitas Pharma?
Averitas Pharma is a specialty pharmaceutical company established in 2018, operating as a subsidiary of GRT U.S. Holding, Inc. and a member of the Grünenthal Group. The company is dedicated to developing and delivering innovative, non-opioid pain management solutions to patients across the U.S. Its focus on alternatives to traditional opioid treatments places it in a critical segment of the healthcare market, addressing a significant unmet medical need.
How much funding has Averitas Pharma raised?
Averitas Pharma has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Averitas Pharma?
The recent large-scale, late-stage funding indicates Averitas Pharma is poised for significant expansion and market penetration. This strategic investment will likely fuel further clinical development, regulatory submissions, and commercialization efforts for its pipeline of non-opioid pain therapies. The company's affiliation with the Grünenthal Group provides a strong foundation for global reach and resource leverage as it advances its mission to provide safer pain management options.
See full Averitas Pharma company page
